natureresearch

Corresponding author(s)	Neal Rosen 10/01/2018		
Initial submission	Revised version	X Final submission	

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

	vii.	
n/a	Cor	nfirmed
	X	The $\underline{\text{exact sample size}}$ (n) for each experimental group/condition, given as a discrete number and unit of measurement
	X	An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	X	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	X	A description of all covariates tested
	X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	X	A full description of the statistics including <u>central tendency</u> (e.g. means) or other basic estimates (e.g. regression coefficient) AND <u>variation</u> (e.g. standard deviation) or associated <u>estimates of uncertainty</u> (e.g. confidence intervals)
	X	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
	X	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	X	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	X	Clearly defined error bars State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on statistics for biologists may be useful.

Software and code

Policy information about availability of computer code

Data collection The structural analysis is based on the data acquired from PDB:BRAF-BRAF (PDB: 4E26) and CRAF-CRAF (PDB: 3OMV)

Data analysis The densitometry analysis was done by Image J, all the graphs are generated by Graphpad Prism 6.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

We have included a statement "Source data and all other data supporting this work are provided in Supplementary information." in the Availability of Data.

Field and	ocific reporting			
rieid-spe	ecific reporting			
Please select the b	est fit for your research. If you are not sure, read the appropriate sections before making your selection.			
✓ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences			
Life scier	nces study design			
All studies must dis	sclose on these points even when the disclosure is negative.			
Sample size	Sample size was chosen based on previous studies. The sample sizes have been shown to be sufficient for the statistical analysis.			
Data exclusions	No data were excluded from the analysis.			
Replication	All experimental findings were reliably reproduced.			
	We have indicated the replicates of the experiments in the Figure Legends.			
Randomization	The mice are randomized in each test groups in the animal studies.			
Blinding	All experiments were conducted in unblinded conditions. The experiments are designed based on preliminary data and pilot experiments, and			
	a detail protocol is required for the animal core to run the studies.			
Reporting for specific materials, systems and methods				
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods				
n/a Involved in the study n/a Involved in the study				
Unique biological materials ChIP-seq				
Antibodies Flow cytometry				
Eukaryotic cell lines MRI-based neuroimaging				
Palaeontology Animals and other organisms				
	Human research participants			
Antibodies				
Antibodies used	Western blot and immunoprecipitation (IP) were performed as described1,20. Antibodies used include: anti-p217/p221-MEK1/2			
	(p-MEK1/2) (#9154, lot#14), anti-p202/p204-ERK1/2 (p-ERK1/2) (#4370, lot# 17), anti-MEK1/2 (#4694, lot# 6), and anti-ERK1/2 (#4696, lot# 16) from Cell Signaling; anti-V5 (46-1157, lot# 1902786) from Invitrogen; anti-BRAF (cat# sc-5284, lot# C0116), anti-			
	Cyclin D1 (cat# sc-718, lot# G1411) and anti-ARAF (cat# sc-166771, lot# A2617) from Santa Cruz Biotechnology; anti-FLAG (cat# F1804, lot# SLBT7654) from Sigma; anti-CRAF (cat# 610152, lot#7208706) from BD Transduction Laboratories; and anti-RAS			
	(cat# 1862335, Lot # \$1259698) from the active RAS pull-down and detection kit (Thermo Fisher Scientific, cat# 16117). For			
	immunoprecipitations of tagged proteins, we used: anti-V5 agarose affinity gel (Sigma, cat# A7345, lot# SLBR7667V) and anti- FLAG M2 affinity gel (Sigma, cat# F1804, lot# SLBT7654), protein G agarose gel (Thermo Fisher Scientific cat# 15920010). The			
	secondary antibodies used for Western blot are: goat anti-rabbit, HRP (Sigma, cat# A4914, lot# SLBM7730U) and donkey anti-			
	mouse, HRP (Amersham, cat# NXA931, lot# 9708064). The primary antibodies used in Western Blot are diluted in 1:1,000, secondary antibodies are diluted in 1:5,000. The antibodies used in IP assay, are diluted in 1:200. All these antibodies have been			
	validated in the previous studies			

All the antibodies have been validated in our previous work.

Eukaryotic cell lines

Policy information about <u>cell lines</u>

Cell line source(s)

Validation

Cell lines A375: CRL-1619, 22Rv1: CRL-2505, H1666: CRL-5885, H508: CCL-253, H661: HTB-183, SKBR3: HTB-30, A549: CCL-185, BEAS-28: CRL-9609, primary epidermal melanocytes: PCS-200-012 and primary epidermal keratinocytes: PCS-200-011 was obtained from American Type Culture Collection. SK-MEL-239, SK-MEL-239 C4, SK-MEL-2, SK-MEL-30, SK-MEL-246 and SK-MEL-285 were from MSKCC cell collection. CAL-12T: ACC433 and JVM-3: ACC18 were from DSMZ. 293H cells

(#11631017) were purchased from ThermoFisher Scientific. MDST8 cells were from Millipore Sigma (#99011801). The

conditional RAF knockout MEF cell line was from M. Barbacid lab.

Authentication All the cell lines used in this study have been validated in previous work. Genetic alterations in cell lines from the MSKCC cell

collection were confirmed by IMPACT sequencing.

Mycoplasma contamination All cell lines tested negative for mycoplasma.

Commonly misidentified lines (See ICLAC register)

No Commonly misidentified cell lines are used in this study.

Animals and other organisms

Policy information about studies involving animals: ARRIVE guidelines recommended for reporting animal research

Laboratory animals 4-6 weeks old, female NSG mice were used in this study.

Wild animals The study did not involve wild animals.

Field-collected samples No field-collected samples are used in this study

Human research participants

Policy information about studies involving human research participants

Population characteristics Tumor samples were collected from MSK patients (Patient with BRAF G466V tumor: 55yo, Female, (Right) colon cancer, PDX

collected after treatment with standard chemotherapy; Patient with BRAF K601E tumor: 41yo, Female, (Left) colon cancer, PDX collected after treatment with standard chemotherapy; no patient has received RAF inhibitor treatment when the samples are

collected)

The patient tumor samples were was transplanted orthotopically into NSG mice to make the PDX (IRB protocols 06-107, 14-091 (13)). Studies were performed in compliance with institutional guidelines under an IACUC approved protocol and all analysis of

human tissues was conducted under institutional Review Board/Privacy Board approved protocol.

Recruitment The patients are not recruited for specific study. The Patient samples are defined by IMPACT sequencing and selected by certain

genetic alterations. The Patient ID information have been removed when samples are collected.

